slight male predilection (male: female 1.2:1) and Caucasians are much more frequently affected than Asians and Africans [7, 8] . Lower extremities are the most common site of bone disease (43%) while extraosseous primary tumors mostly occur in the trunk (32%) (Fig 2) . Metastatic disease is present at diagnosis in about 20-25% of patients and affects the lungs, other bones or multiple systems [5, 9] .
Biology & Pathology
The World Health Organisation (WHO) classification uses EWS/primitive neuroectodermal tumor (PNET) as an inclusive term which encompasses classic EWS, Askin tumor of the thoracic wall, Ewing tumor, peripheral neuroepithelioma, peripheral neuroblastoma, Ewing family of tumors and Ewing sarcoma family of tumors [10] . EWS is derived from a primordial bone marrow-derived mesenchymal stem cell [11, 12] . Histologically, EWS is characterised by a monotonous population of small round blue cells with a low mitotic activity of 15-20%. Cytoplasmic glycogen is abundant which gives periodic acid-Schiff (PAS) positivity [13] . The MIC2 gene product, CD99, a surface membrane glycoprotein is overexpressed [14] but it is not specific for EWS. Neural differentiation is evident in the form of positive vimentin in approximately one third of cases. A reciprocal chromosomal translocation involving the EWSR1 gene on chromosome 22 band q12 combined with any of a number of partner chromosomes is pathognomonic of the diagnosis of EWS. The breakpoint was first cloned in the 1990s [12, 15] . Although abnormalities of chromosome 11 are involved in 95% of cases [16] , the translocation may involve chromosomes 21, 7 and 17 uncommonly [17, 18] . The fusion protein resulting from this chromosomal rearrangement is a potent transcriptional factor which inappropriately activates the target genes, thereby exerting the oncogenic activity. Other numerical and structural alterations seen in EWS are gains of chromosomes 2, 5, 8, 9, 12, and 15 ; deletions on the short arm of chromosome 6; the nonreciprocal translocation t(1;16)(q12;q11.2); and trisomy 20 [19, 20] . 
Staging

Prognosis
The 5 year survival rate for EWS was less than 10% before the advent of modern chemotherapy [28, 29] [52, 53] and patients relapsing less than two 
Treatment options
Chemotherapy for a total of 10-12 months before and after local control is common practice [33, 55] . Initial chemotherapy aims to shrink the tumor to increase to probability of effective local control. Alkylating agents, mainly ifosfamide and cyclophosphamide and anthracyclines form the chemotherapeutic backbone Etoposide, vincristine and actinomycin-D make up the remainder of the four-to five-drug combination chemotherapy.
Chemotherapy for newly diagnosed patients:
Clinical trials in the early years (pre-1990) Before 1960s, radiation therapy and surgery were used for the treatment of EWS which provided adequate control of the primary disease but patients invariably died of metastatic disease [56] . Chemotherapy was added based on the hypothesis that, in most cases of apparently localized disease, tumor cells were already disseminated without clinical manifestations. Single chemotherapy agents including cyclophosphamide [57, 58, 59] and subsequent studies established a survival benefit of their addition to VACD [78]. National Cancer Institute protocol INT0091 was a randomized trial conducted by the Children's Cancer Group (CCG) and Pediatric Oncology Group (POG) from 1988 through 1992. Patients were assigned to receive VACD or VACD plus ifosfamide and etoposide (VACD-IE). In patients without metastatic disease, the five-year EFS for the VACD group was 54% while the same for the VACD-IE group was 69%. These results established VACD-IE as the gold standard for the treatment of localised Ewing sarcoma [30] . Clinical trials for standard risk (SR) and high risk (HR) EWS since 1990
The disease risk stratification into SR and HR has varied depending on the trial but in general SR means localized small tumors (<200 mL), or tumors with a good histological response to preoperative chemotherapy (<10% cells). HR tumors include metastatic tumors, or large localized tumors (>200 mL). The trials for SR EWS have tried to address the important questions like the superiority of one alkylating agent over the other (cyclophosphamide and ifosfamide) and survival advantage by dose intensification or addition newer chemotherapy agents.
Cyclophosphamide vs Ifosfamide
Historically, cyclophosphamide was used for the treatment of EWS. Promising results were seen with ifosfamide in relapsed patients who did not respond to cyclophosphamide [83] . It was postulated that 9 g/m2 of ifosfamide was equimyelotoxic to 2.1 g/m2 of cyclophosphamide [84] . With the potential for less myelotoxicity and high-dose administration, cyclophosphamide was replaced with ifosfamide in the 1980s. But the results of these non-randomized, singlearm studies were mixed, with one study showing no benefit [ 
Local therapy
The goal of local therapy is to maximize the local control with minimal morbidity. Surgery and radiation therapy are the two local control modalities employed for EWS. No randomized trials have compared these and as such their relative roles remain controversial [13] .
Surgical resection provides information about the amount of tumor necrosis and may be less morbid in the younger patients. [111] or with carboplatin and etoposide (ICE) has been commonly used with survival rates between 29%-33% [112, 113] . Cyclophosphamide and topotecan combination achieved response rates of 23%-44% with low toxicity and an added advantage of outpatient administration [114, 115] but with a small median duration of response of 8 months [116] . Response rates of 29% to 68% and median time to progression of 3 to 8.5 months were seen with irinotecan and temozolomide [117, 118, 119, 120] . Diarrhea was a troublesome complication which was managed effectively with oral cephalosporins. The combination was otherwise well tolerated. Although gemcitabine and docetaxel showed activity in one study [121] , the results were not confirmed by subsequent studies. [122] .
In case of recurrent EWS, the addition of HDT to salvage regimens is controversial. Some studies showed a good response in specific groups of patients who responded to relapse therapy and underwent HDT with OS rates of 53 to 66% [123, 124] , but most of the reports indicate HDT does not improve prognosis [54, 125, 126] .
Targeted therapy for EWS Tyrosine kinase (TK) inhibitors
TKs are important modulators of growth factor signaling and play a critical role in tumor growth. TK inhibitors are used alone or in combination with conventional chemotherapy agents in treatment of various cancers (127) . A number of TK inhibitors have been tried in EWS with variable response.
Insulin-like growth factor 1 receptor (IGF1R) inhibitors IGF1R is necessary for growth and development of normal as well as cancer cells [128] . With promising pre-clinical results showing IGF1R inhibition in EWS cell lines and xenografts [129] , more than 25 agents inhibiting IGF1R are currently under investigation [130] . Histone deacetylase (HDAC) inhibitors HDAC inhibition suppresses EWS-FLI1 expression and may represent a novel therapeutic target for EWS (151) .
Mammalian target of rapamycin (mTOR) inhibitors MTOR is a serine/threonine kinase with critical role in protein synthesis, cell growth and proliferation regulation. mTOR inhibitors have shown activity in preclinical models. A phase I study of temsirolimus, irinotecan and temozolomide demonstrated efficacy and tolerability [152] . But another phase II study of temsirolimus with cixutumumab did not show any objective response despite the encouraging preclinical data [153] . Ridaforolimus was associated with a statistically significant but clinically small benefit on PFS [154] .
Aurora A kinase inhibitors Although alisertib (MLN8237), an Aurora
A kinase inhibitor produced promising results in the Pediatric Preclinical Testing Program [155] , a recently concluded Children's Oncology Group phase II trial failed to establish its efficacy in EWS [156] .
Hedgehog pathway modulation Arsenic trioxide was effective in inhibiting EWS growth in preclinical cell culture models by targeting p38(MAPK) and c-Jun N-terminal kinase [157] . These observations warrant further investigation.
Bisphosphonates
Zoledronic acid acts by inducing apoptosis by upregulating osteoprotegerin which was the basis of activity seen in EWS preclinical models [158, 159] . However, confirmatory clinical trials have not been performed.
Immune therapy
Interleukin-15-activated natural killer (NK) cells combined with HDAC inhibitors improve immune recognition of therapy-sensitive and -resistant EWS and sensitize for NK cell cytotoxicity [160] . Allogenic NK cells have shown activity against EWS cells on their own [161].
EWS-FLI1 targeting
Targeting the EWS-FLI1 fusion protein or its key signalling pathway is another attractive approach [162] . YK-4279, a small molecule inhibitor of EWS-FLI1 protein activity [163, 164] , mithramycin, a chemotherapy drug [165] and midostaurin (PKC412), a multikinase inhibitor [166] have shown activity in preclinical models.
Many advances have been made in the management of EWS since its first description almost 100 years ago. Molecular and imaging techniques are progressing at a rapid pace allowing for newer insights into the biology of this disease. From radiation therapy alone, the treatment has evolved to include multiple modalities. The outcome for localized disease has improved dramatically but more needs to be done for patients with metastatic or recurrent EWS. Targeted therapies may offer some hope for the latter group.
Conclusion
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